Cancer cells might develop compensatory mechanisms that bypass Nrf2 inhibition, such as activating alternative pathways for detoxification and survival, thereby reducing the effectiveness of Nrf2-targeted therapies. The gene discussed is NFE2L2; the disease is cancer.